Share-based Payment Arrangement, Expense of Inozyme Pharma, Inc. from 30 Jun 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inozyme Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 31 Mar 2025.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $1,857,000, a 9.8% increase year-over-year.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $8,111,000, a 22% increase year-over-year.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,945,000, a 13% increase from 2023.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,037,000, a 8.6% decline from 2022.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,700,000, a 6.9% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Inozyme Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $8,111,000 $1,857,000 +$166,000 +9.8% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $7,945,000 $1,971,000 +$298,000 +18% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $7,647,000 $2,126,000 +$454,000 +27% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $7,193,000 $2,157,000 +$557,000 +35% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $6,636,000 $1,691,000 -$401,000 -19% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $7,037,000 $1,673,000 -$241,000 -13% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $7,278,000 $1,672,000 -$177,000 -9.6% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $7,455,000 $1,600,000 -$585,000 -27% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $8,040,000 $2,092,000 +$340,000 +19% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $7,700,000 $1,914,000 -$144,000 -7% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $7,844,000 $1,849,000 +$97,000 +5.5% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $7,747,000 $2,185,000 +$372,000 +21% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $7,375,000 $1,752,000 +$175,000 +11% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $7,200,000 $2,058,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $1,752,000 +$966,000 +123% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,813,000 +$1,693,000 +1411% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $1,577,000 +$1,448,000 +1122% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $786,000 +$679,000 +635% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $120,000 +$80,000 +200% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $129,000 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q3 2019 $107,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $40,000 01 Apr 2019 30 Jun 2019 10-Q 03 Sep 2020 2020 Q2

Inozyme Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,945,000 +$908,000 +13% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $7,037,000 -$663,000 -8.6% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $7,700,000 +$500,000 +6.9% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $7,200,000 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.